Skip to content
Screener

Vaxcyte, Inc. PCVX Business Segments — Total other income, net

Similar metrics at other companies

Crinetics Pharmaceuticals logo
CRNXReportable Segment — Total other income, net
$12.53M-14.3%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Total other income, net
$193K-87.0%
LiveRamp Holdings, Inc. logo
RAMPReportable Segment — Total other income, net
$3.09M-16.7%
Enphase Energy logo
ENPHReportable Segment — Total other income, net
$10.38M+99.7%
Prime Medicine logo
PRMEReportable Segment — Total other income, net
$1.18M+49.6%
Bicara Therapeutics logo
BCAXReportable Segment — Total other income
$4.08M-18.6%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$8.07B+89.7%
Enterprise value$7.93B+96.5%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001649094-26-000017

| Operating expenses: | | | | Research and development - external costs (1) | $256,432 | $103,806 | | Research and development - internal costs (2) | 56,347 | 44,328 | | General and administrative | 33,071 | 32,659 | | Total operating expenses | $345,850 | $180,793 | | Total other income, net | 25,228 | 40,075 | | Net loss | $320,622 | $140,718 |

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Vaxcyte, Inc.'s business segments — total other income, net?
Vaxcyte, Inc. (PCVX) reported business segments — total other income, net of $25.23M in Q1 2026.
How has Vaxcyte, Inc.'s business segments — total other income, net changed year-over-year?
Vaxcyte, Inc.'s business segments — total other income, net decreased by 37.0% year-over-year, from $40.08M to $25.23M.
What is the long-term trend for Vaxcyte, Inc.'s business segments — total other income, net?
Over 3 years (2022 to 2025), Vaxcyte, Inc.'s business segments — total other income, net has grown at a 161.6% compound annual growth rate (CAGR), from $8.77M to $157.05M.
What does business segments — total other income, net mean?
This metric represents the net financial results from activities outside of the segment's primary operational focus, such as interest income, investment gains, or other non-core financial items. It reflects the segment's ability to generate supplemental returns on its cash reserves or other assets. A positive value indicates that non-operating activities are contributing to the segment's overall financial position.

Ask your AI about Vaxcyte, Inc.'s business segments — total other income, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude